Moderna, Inc. share price logo

Moderna, Inc. Share Price

NASDAQ: MRNA

Large Cap

$25.70

+0.70

(+2.80%)

Live

as on

Moderna, Inc. Stock Performance

as on September 18, 2025 at 7:42 pm IST

  • Day's Low

    Day's High

    $25.2
    $25.92
    downward going graph

    1.95%

    Downside

    0.86%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $23.15
    $73.35
    downward going graph

    9.92%

    Downside

    185.41%

    Upside

    downward going graph

Moderna, Inc. share price movements today

Previous Close
$25.00
Open
$25.62
Volume
2.0M
Day's Low - High
$25.2 - $25.92
52 Week Low - High
$23.15 - $73.35

Moderna, Inc. Historical Returns

1 Month Return
-11 %
3 Month Return
-1.57 %
1 Year Return
-64.21 %
3 Year Return
-81.85 %
5 Year Return
-64.22 %

Moderna, Inc. Stock Fundamentals & Key Indicators

Check Moderna, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$9.7B

EPS (TTM)

-9.7831

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.85%

PE Ratio (TTM)

-5.08

Industry PE ratio

16.65525641025641

P/B Ratio

0

PEG Ratio

0

EBITDA

-3.1B

Revenue (TTM)

3.1B

Profit Margin

-94.31%

Return On Equity TTM

456589700.00%

Moderna, Inc. Stock Valuation

Track how Moderna, Inc. P/E has moved over time to understand its valuation trends.

Moderna, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (4.36x)

June 30, 2022

Today (-5.08x)

September 18, 2025

Industry (16.66x)

September 18, 2025

Highest (115.93x)

March 31, 2021

LowHigh

Today’s Price to Earnings Ratio: -5.08x

Moderna, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Moderna, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$9.7B-64.22%-5.08-94.31%
BUY$60.5B241.54%-505.15-12.96%
NA$38.7BNANA-3.89%
BUY$99.3B45.88%27.5631.86%
BUY$60.9B5.45%14.4931.37%

Stock Returns calculator for Moderna, Inc. Stock including INR - Dollar returns

The Moderna, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Moderna, Inc. investment value today

Current value as on today

₹41,741

Returns

₹58,259

(-58.26%)

Returns from Moderna, Inc. Stock

₹63,212 (-63.21%)

Dollar Returns*

₹4,953 (+4.95%)

Analyst Recommendation on Moderna, Inc. Stock

Based on 31 analysts

BUY

54.84%

Buy

35.48%

Hold

9.68%

Sell

Based on 31 analysts, 54.84% of analysts recommend a 'BUY' rating for Moderna, Inc.. Average target price of $44.25

Moderna, Inc. Share Price Target

Get share price movements and forecasts by analysts on Moderna, Inc..

What analysts predicted

41.92%UPSIDE

Target Price

$44.25

Current Price

$25.7

Analyzed by

31 Analysts

Target

$44.25

Moderna, Inc. target price $44.25, a slight upside of 41.92% compared to current price of $25.7. According to 31 analysts rating.

Moderna, Inc. Stock's Interest Amongst Investors

Investment in Moderna, Inc. Shares on INDmoney has grown by 86.86% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:86.86% versus previous 30 day period

Search interest for Moderna, Inc. Stock has increased by 53% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:53% versus previous 30 day period

Moderna, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
1,838
344
1,831
2,813
167
221
1,855
956
107
142
Gross Profit
1,046
-387
-410
1,884
71
106
1,341
217
17
23
Operating Income
-366
-1,867
-2,012
6
-1,266
-1,363
-70
-1,246
-1,050
-907
EBITDA
-218
-1,646
-1,699
278
-1,123
-1,232
79
-1,118
-924
-760
Interest Expense
9
13
10
6
6
6
6
6
1
1
Depreciation
78
92
249
202
36
41
52
60
39
57
Income Before Tax
-305
-1,749
-1,958
70
-1,165
-1,279
21
-1,184
-964
-818
Income Tax Expense
-384
-369
1,672
-147
10
-
8
-64
7
7
Net Income
79
-1,380
-3,630
217
-1,175
-1,279
13
-1,120
-971
-825
Net Profit Margin
4.30%
-401.16%
-198.25%
7.71%
-703.59%
-578.73%
0.70%
-117.15%
-907.48%
-580.99%

Moderna, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
108
205
122
48
274
17,736
18,875
6,848
3,199
Gross Profit
-
93
185
-331
48
266
15,119
13,459
2,155
1,735
Operating Income
-1
-223
-269
-413
-545
-763
13,296
9,420
-4,239
-3,945
EBITDA
-
-208
-235
-388
-514
-731
13,528
9,768
-3,283
-3,394
Interest Expense
-
-
0
3
6
9
18
29
38
24
Depreciation
-
-
20
24
31
31
232
348
499
189
Income Before Tax
-1
-215
-255
-384
-514
-744
13,285
9,575
-3,942
-3,607
Income Tax Expense
0
1
0
0
0
2
1,083
1,213
772
-46
Net Income
-1
-216
-255
-384
-514
-747
12,202
8,362
-4,714
-3,561
Net Profit Margin
0.00%
-199.46%
-124.34%
-314.04%
-1070.07%
-272.16%
68.80%
44.30%
-68.84%
-111.32%

Moderna, Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-1,380
-3,630
217
-1,175
-1,279
13
-1,120
-971
-825
Operating Cash Flow
-915
-1,600
622
-989
-1,274
-1,566
825
-1,037
-919
Investing Cash Flow
1,944
789
-538
118
1,649
721
-539
730
564
Financing Cash Flow
-668
-58
-109
14
34
11
-3
4
9
Change in Cash
361
-869
-25
-857
409
-833
282
-303
-345

Moderna, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-216
-255
-384
-514
-747
12,202
8,362
-4,714
-3,561
Operating Cash Flow
66
-331
-330
-458
2,026
13,620
4,981
-3,118
-3,004
Investing Cash Flow
-648
416
-372
-14
-1,671
-8,523
-5,176
4,206
1,949
Financing Cash Flow
472
0
1,226
51
2,033
-873
-3,448
-1,377
56
Change in Cash
-108
84
523
-422
2,388
4,224
-3,643
-289
-999

Global Institutional Holdings in Moderna, Inc.

Funds
Holdings
Vanguard Group Inc
10.38%
BlackRock Inc
6.99%
Baillie Gifford & Co Limited.
5.68%
FMR Inc
5.43%
State Street Corp
4.57%

Moderna, Inc. News & Key Events

  • img

    Today's Timeline - 16 September

    Tue, 04:36 PM

    -

    Increased scrutiny over vaccine safety impacts Moderna's investment narrative amid ongoing R&D momentum.

    Tue, 08:19 PM

    -

    Moderna announces positive preliminary data for its updated Spikevax COVID-19 vaccine targeting the LP.8.1 variant.

    Tue, 09:10 PM

    -

    Moderna shares rise 4% after positive vaccine data; UBS maintains Buy rating with a $70 price target.

Insights on Moderna, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 107.0M → 142.0M (in $), with an average increase of 24.7% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -1.12B → -825.0M (in $), with an average increase of 16.5% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 132.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 193.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, MRNA stock has moved down by -11.0%

About Moderna, Inc.

"Moderna is a pharmaceutical and biotechnological company founded in 2010 in Massachusetts, the United States, by 'Derrick Rossi', 'Timothy A. Springer', 'Robert S. Langer', 'Kenneth R. Chien', 'Noubar Afeyan'. The CEO of this company is Stephan Bancel. The company aims to provide primarily mRNA vaccines and RNA therapeutics. They use a copy of messenger RNA to create vaccines for immune response in a body. The company develops and discovers drugs capable of producing antibodies in the patient's cells. The company develops and produces human proteins, antibodies, and novel proteins using mRNA therapeutics, which helps prevent, treat, and cure disease. The only commercial product of this company right now is the "Moderna COVID-19 vaccine". The Moderna Company has about twenty-three treatments and vaccine aspirants; fifteen have already been moved into the clinical trials. These vaccine aspirants consist of respiratory virus, chikungunya, single-shot COVID-19 booster, and many more. The company's therapeutic areas are infectious diseases, immuno-oncology, rare diseases, cardiovascular disease, and auto-immune disease. The company's revenue is $803.4 million, and the company's capitalisation, including cash equivalents and investments, is $12.2 billion. The company is currently developing clinical programs to create mRNA medicines for various diseases and conditions. They have made significant advancements in pioneering new vaccines and therapeutics that are capable of treating rare diseases MMA (Methylmalonic Acidemia) and PA (Propionic Acidemia) and preventing diseases like CMV (cytomegalovirus), Zika, and cancer. The company currently has twenty-three development programs and fifteen centred clinical studies. The company has developed relations with several pharmaceutical and biotechnological companies, government organisations, foundations and research institutions with experience and knowledge to fuel the project. Some of the notable companies in the Moderna portfolio include 'AstraZeneca', 'Merck', 'Vertex', 'Barda', 'Bill and Melinda Gates', 'Darpa', 'Institut Pasteur', and 'Karolinska'. Currently Moderna, Inc. has a market cap of $9.73 Billion. It has a P.E ratio of -5.08. The shares of Moderna, Inc. are trading at {current share price in dollars (in INR)}."
OrganisationModerna, Inc.
Headquarters325 Binney Street, Cambridge, MA, United States, 02142
IndustryHealth Technology
CEOMr. Stéphane Bancel
E-voting on sharesClick here to vote

Key Management of Moderna, Inc.

Name

Title

Ms. Tracey Franklin

Chief People & Digital Technology Officer

Mr. Dave Johnson

Chief Data & AI Officer

Dr. Charbel Haber M.P.H., Ph.D.

Senior VP & Head of Global Regulatory Science

Mr. Stéphane Bancel

CEO & Director

Dr. Stephen Hoge M.D.

President

Mr. James M. Mock

Chief Financial Officer

Ms. Shannon Thyme Klinger J.D.

Chief Legal Officer & Corporate Secretary

Dr. Jerh Collins Ph.D.

Chief Technical Operations & Quality Officer

Ms. Lavina Talukdar CFA

Senior VP & Head of Investor Relations

Dr. Melanie Ivarsson M.B.A., O.B.E., Ph.D.

Chief Development Officer

FAQs

What is Moderna, Inc. share price today?

Moderna, Inc. share price today is $25.7 as on . Moderna, Inc. share today touched a day high of $25.92 and a low of $25.2.

What is the 52 week high and 52 week low for Moderna, Inc. share?

Moderna, Inc. share touched a 52 week high of $73.35 on and a 52 week low of $23.15 on . Moderna, Inc. stock price today i.e. is trending at $25.7,which is 64.96% down from its 52 week high and 11.02% up from its 52 week low.

What is Moderna, Inc.'s market capitalisation today?

Moderna, Inc. market capitalisation is $0.01T as on .

How to invest in Moderna, Inc. Stock (MRNA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Moderna, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Moderna, Inc. Shares that will get you 0.0584 shares as per Moderna, Inc. share price of $25.7 per share as on September 18, 2025 at 7:42 pm IST.

What is the minimum amount required to buy Moderna, Inc. Stock (MRNA) from India?

Indian investors can start investing in Moderna, Inc. (MRNA) shares with as little as ₹88.114 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Moderna, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Moderna, Inc. share’s latest price of $25.7 as on September 18, 2025 at 7:42 pm IST, you will get 0.3891 shares of Moderna, Inc.. Learn more about fractional shares .

What are the returns that Moderna, Inc. has given to Indian investors in the last 5 years?

Moderna, Inc. stock has given -64.22% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?